For research use only. Not for therapeutic Use.
Teplinovivint is a potent wnt/β-catenin signaling pathway inhibitor. Teplinovivint has anti-inflammatory activity and has the potential for tendinopathy research[1].
Teplinovivint (compound 175; 0.0003-10 μM) inhibits Wnt/p-catenin activity in human colorectal cancecell line (SW480) in a dose-dependent manner (EC50=152.9 nM)[1].
Teplinovivint inhibits SW480 cells (EC50=25 nM) and primary human mesenchymal stem cells (hMSCs; EC50=10.377 μM)[1].
Teplinovivint (5.8, 10.8, 21.7, 41.7, 83.3, 166.6, 333.3, 750 nM) induced the expression of SCXA, TenacinC and Tenomodulin, in a dose-dependent manner with an EC50 between 139-189 nM[1].
Teplinovivint (compound 175; 10 mg/ml; once daily for 21 days via topical application) causes amelioration of inflammation as well as tendon degeneration. Teplinovivint results in a decrease of aninflammatory plasma biomarker, KC/GRO in the Collagenase-induced Tendon Injury Model[1].
Teplinovivint (1 mg/ml with 1% BA) has a Tmax of 1 hours in plasma[1].
| Catalog Number | I037123 |
| CAS Number | 1428064-91-8 |
| Synonyms | N-(6-methoxypyridin-3-yl)-5-[5-(piperidin-1-ylmethyl)pyridin-3-yl]-1H-indazole-3-carboxamide |
| Molecular Formula | C25H26N6O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H26N6O2/c1-33-23-8-6-20(15-27-23)28-25(32)24-21-12-18(5-7-22(21)29-30-24)19-11-17(13-26-14-19)16-31-9-3-2-4-10-31/h5-8,11-15H,2-4,9-10,16H2,1H3,(H,28,32)(H,29,30) |
| InChIKey | YDPWZFPXWFTXNT-UHFFFAOYSA-N |
| SMILES | COC1=NC=C(C=C1)NC(=O)C2=NNC3=C2C=C(C=C3)C4=CN=CC(=C4)CN5CCCCC5 |
| Reference | [1]. Vishal DESHMUKH, et al. Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors. WO2018075858A1. |
